PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11207317-5	2001	In this study, we examined whether cis-diaminedichloroplatinum (II) cisplatin (CDDP) sensitizes MART-1/HLA A2.1(+) melanoma and melanoma variant tumor cells to non-MHC-restricted, Fas ligand (FasL)-mediated killing by CTL.	Cisplatin	68-77	major histocompatibility complex, class I, C	Homo sapiens	164-167	
11207317-5	2001	In this study, we examined whether cis-diaminedichloroplatinum (II) cisplatin (CDDP) sensitizes MART-1/HLA A2.1(+) melanoma and melanoma variant tumor cells to non-MHC-restricted, Fas ligand (FasL)-mediated killing by CTL.	Cisplatin	79-83	major histocompatibility complex, class I, C	Homo sapiens	164-167	
10397471-1	1998	This paper examines the monohydrated complex of cisplatin (MHC) with respect to kinetics and cytotoxicity.	Cisplatin	48-57	major histocompatibility complex, class I, C	Homo sapiens	59-62	
10397471-9	1998	At a pH of between 6.0 and 7.2, MHC was rapidly converted to cisplatin.	Cisplatin	61-70	major histocompatibility complex, class I, C	Homo sapiens	32-35	
10397471-11	1998	These findings might have clinical significance given that MHC circulates in the blood stream of patients receiving cisplatin infusions and that solid tumours often have environments that are extremely acidotic.	Cisplatin	116-125	major histocompatibility complex, class I, C	Homo sapiens	59-62	
34686187-11	2021	We also demonstrated the in vitro and in vivo efficacies of pNK cells against cisplatin-resistant A2780cis ovarian cancer cells having a high programmed death-ligand 1(PD-L1) and low HLA-C expression.	Cisplatin	78-87	major histocompatibility complex, class I, C	Homo sapiens	183-188	
34124164-6	2021	We found that cisplatin treatment led to dramatically decreased cell viability; accumulated ROS level; down-regulated expressions of MyoD1 (myoblast determination protein 1), myogenin, and MHC (myosin heavy chain); and impaired myotube differentiation in myoblasts.	Cisplatin	14-23	major histocompatibility complex, class I, C	Homo sapiens	189-192	
34124164-6	2021	We found that cisplatin treatment led to dramatically decreased cell viability; accumulated ROS level; down-regulated expressions of MyoD1 (myoblast determination protein 1), myogenin, and MHC (myosin heavy chain); and impaired myotube differentiation in myoblasts.	Cisplatin	14-23	major histocompatibility complex, class I, C	Homo sapiens	194-212